Conference Day One

September 22, 2025

PART ONE: FIND YOUR FUTURE PARTNER

Bringing you a targeted and scientifically aligned partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format to find your next partner and route to more capital

8.10-9.00

Interest across emerging targets and modalities and alignment for collaborations from the Pharma Icebreaker

9.15-10.45

Face-to-face matchmaking for protected networking time during the Pharma Matchmaking Roundtables to qualify, hear feedback, and generate interest for the rest of the conference

11.30-12.10

Map venture interest in autoimmunity, from early innovation and specific assets to asset maximization and broad platforms in the Venture Icebreaker

12.10-12.45

Connect with Investors to effectively align business development and investment goals in the Investor Matchmaking Session

7:00 am One-on-One PartneringTM portal meeting schedule starts

Synopsis

Grab a coffee and sit down with key contacts in the hour before the conference at bookable meeting spaces

8:00 am Chair’s Opening Remarks

8:10 am Pharma Icebreaker: Partnering & Innovation in Autoimmunity: Targets, Modalities & Next Generation Biologics

Synopsis

  • Exploring pharma’s evolving strategy across known targets, new modalities, and combination therapies to shape future partnering discussions
  • Evaluating autoimmune cell therapy and next generation biologics to understand their capacity to drive future investments
  • Uncovering key competitive differentiators prioritised in search and evaluation processes to drive deal-making and partnership decisions

9:00 am Comfort Break Ahead of Networking Session

9:15 am Pharma Matchmaking Tables

Synopsis

  • Pharma Icebreaker Tables offers face-to-face interactions with the highest value contacts, whether your connecting on the One-to-one Partnering portal or not, this is your guaranteed chance to break the ice
  • Two weeks out from the conference, attending pharma and biotech companies will review each other and make selections to meet companies they haven’t already scheduled 1:1 meetings with. Each pharma company will have a table and with these selections, we will build a schedule of biotech company rotations across 90 minutes

10:45 am Morning Break

11:00 am One-to-One Meeting Opportunity

11:30 am Investor Icebreaker: When Being Selective, What Will Investors Choose?

Synopsis

  • Understanding venture focus across asset-centred investments and early-stage innovation to guide strategic investment discussions
  • Discussing preferences for broad platforms or highly specific assets to understand asset maximization from a venture perspective
  • Identifying exciting modalities, underestimated modalities and targets gaining traction in the global market to anticipate the next wave of autoimmune innovation

12:10 pm Investors Matchmaking Tables:

Synopsis

  • Straight after the Investor Icebreaker, join high tables in small groups with an investor at each table. Biotech will remain, while investors move table to table
  • Rapidly gauge alignment between portfolios and stage of company, share business cards, or ask follow-up questions from the panel before the investors rotate and a new round begins

12:45 pm Lunch & Networking

2:00 pm One-to-one Meeting Schedule Pauses for Presentations to Start

Harnessing In Vivo Therapies to Optimize Autoimmune Treatment Delivery, Safety & Efficacy

2:10 pm Company Presentation

Synopsis

  • Are you a company specialising in in vivo therapies?
  • Providing opportunities to provide safe, cheaper and more accessible therapies to patients, pharma and investors have a keen eye on in vivo developments. If you’re looking to showcase your in vivo innovations, get involved in a company presentation.
  • Showcase your innovation in one of our limited, standalone presentation slots giving you the full stage to capture attention of pharma and investor decision-makers to drive partnership opportunities
  • Ensure maximum visibility and engagement with the most relevant decision makers shaping the future of autoimmune and inflammatory deal making

3:10 pm Analyzing In Vivo Approaches, Delivery & Safety to Uncover their Future Potential

Synopsis

  • Exploring the therapeutic potential of in vivo approaches, including in vivo and B-cell depletion to anticipate a future developments
  • Assessing if the rules that govern cancer therapies are applicable to autoimmunity to effectively evaluate knockout strategies with lentiviral vectors or opportunities for redosing with mRNA
  • Debating safety versus efficacy in the context of LNP and LVV delivery, shifting FDA perspectives, and manufacturing challenges to understand the impact on commercial outcome

4:00 pm Drinks Reception

Synopsis

Enjoy an informal networking drinks reception with all attending and presenting companies to catch up with key stakeholders outside of the regular meeting and ahead of BIO or Jeffries in the conference calendar.